Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest

Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 2,915,560 shares, a growth of 11.9% from the January 12th total of 2,605,402 shares. Based on an average daily volume of 244,712 shares, the short-interest ratio is currently 11.9 days. Approximately 9.2% of the shares of the company are sold short.

A hedge fund recently raised its stake in Asterias Biotherapeutics stock. Virtu Financial LLC increased its position in Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) by 387.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,588 shares of the biotechnology company’s stock after acquiring an additional 56,888 shares during the period. Virtu Financial LLC owned approximately 0.13% of Asterias Biotherapeutics worth $161,000 as of its most recent SEC filing.

Asterias Biotherapeutics (NYSEAMERICAN AST) traded down $0.15 during midday trading on Friday, reaching $1.95. The company’s stock had a trading volume of 354,648 shares, compared to its average volume of 277,752. The firm has a market cap of $111.01, a PE ratio of -3.00 and a beta of 1.07. Asterias Biotherapeutics has a 52 week low of $1.95 and a 52 week high of $4.30.

Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.15) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.15). Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%.

Several equities analysts have issued reports on the company. Zacks Investment Research cut Asterias Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright reiterated a “buy” rating on shares of Asterias Biotherapeutics in a research report on Wednesday, November 22nd. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $8.94.

COPYRIGHT VIOLATION NOTICE: “Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/09/asterias-biotherapeutics-inc-ast-sees-significant-growth-in-short-interest.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply